Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Molecular Markers of Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Literature Review.

López-Verdín S, Lavalle-Carrasco J, Carreón-Burciaga RG, Serafín-Higuera N, Molina-Frechero N, González-González R, Bologna-Molina R.

Cancers (Basel). 2018 Oct 10;10(10). pii: E376. doi: 10.3390/cancers10100376. Review.

2.

Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.

Pendleton KP, Grandis JR.

Clin Med Insights Ther. 2013;2013(5). doi: 10.4137/CMT.S10409.

3.

NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC).

Almeida LO, Abrahao AC, Rosselli-Murai LK, Giudice FS, Zagni C, Leopoldino AM, Squarize CH, Castilho RM.

FEBS Open Bio. 2013 Dec 30;4:96-104. doi: 10.1016/j.fob.2013.12.003. eCollection 2014.

5.

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma.

Longton E, Schmit K, Fransolet M, Clement F, Michiels C.

Front Oncol. 2018 Oct 5;8:432. doi: 10.3389/fonc.2018.00432. eCollection 2018.

6.

Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.

Blasco MA, Svider PF, Raza SN, Jacobs JR, Folbe AJ, Saraf P, Eloy JA, Baredes S, Fribley AM.

Laryngoscope. 2017 Nov;127(11):2565-2569. doi: 10.1002/lary.26629. Epub 2017 Jun 5. Review.

PMID:
28581126
7.

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B.

Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review.

PMID:
16050785
8.

Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.

Raju U, Molkentine DP, Valdecanas DR, Deorukhkar A, Mason KA, Buchholz TA, Meyn RE, Ang KK, Skinner H.

Cancer Med. 2015 Jan;4(1):65-74. doi: 10.1002/cam4.345. Epub 2014 Oct 30.

9.

EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair.

Stegeman H, Span PN, Cockx SC, Peters JP, Rijken PF, van der Kogel AJ, Kaanders JH, Bussink J.

Radiat Res. 2013 Oct;180(4):414-21. doi: 10.1667/RR3349.2. Epub 2013 Sep 23.

PMID:
24059677
10.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
11.

[Molecular mechanisms of chemoresistance in head and neck squamous cell carcinoma].

Zhao YX, Sun ZF.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jun 5;31(11):888-891. doi: 10.13201/j.issn.1001-1781.2017.11.018. Review. Chinese.

PMID:
29775010
12.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
13.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

14.

Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.

Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD.

Clin Cancer Res. 2018 Sep 15;24(18):4539-4550. doi: 10.1158/1078-0432.CCR-18-0327. Epub 2018 May 30.

PMID:
29848571
15.

Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.

Hsu DS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY, Yang MH.

Clin Cancer Res. 2010 Sep 15;16(18):4561-71. doi: 10.1158/1078-0432.CCR-10-0593. Epub 2010 Sep 7.

16.

Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice.

Wang Y, Dong L, Bi Q, Li X, Wu D, Ge X, Zhang X, Fu J, Zhang C, Wang C, Li S.

Target Oncol. 2010 Dec;5(4):237-43. doi: 10.1007/s11523-010-0164-3. Epub 2010 Nov 18.

PMID:
21086056
17.

Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies.

Stein AP, Swick AD, Smith MA, Blitzer GC, Yang RZ, Saha S, Harari PM, Lambert PF, Liu CZ, Kimple RJ.

Cancer Med. 2015 May;4(5):699-712. doi: 10.1002/cam4.387. Epub 2015 Jan 26.

18.

Combination antiangiogenic therapy and radiation in head and neck cancers.

Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS, Mirshahidi S.

Oral Oncol. 2014 Jan;50(1):19-26. doi: 10.1016/j.oraloncology.2013.10.003. Epub 2013 Oct 23. Review.

PMID:
24269532
19.

Pharmacotherapy of head and neck squamous cell carcinoma.

Pan Q, Gorin MA, Teknos TN.

Expert Opin Pharmacother. 2009 Oct;10(14):2291-302. doi: 10.1517/14656560903136754. Review.

PMID:
19663637
20.

A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.

Tonigold M, Rossmann A, Meinold M, Bette M, Märken M, Henkenius K, Bretz AC, Giel G, Cai C, Rodepeter FR, Beneš V, Grénman R, Carey TE, Lage H, Stiewe T, Neubauer A, Werner JA, Brendel C, Mandic R.

J Cancer Res Clin Oncol. 2014 Oct;140(10):1689-704. doi: 10.1007/s00432-014-1727-y. Epub 2014 Jun 10.

PMID:
24913304

Supplemental Content

Support Center